Cannabis does not treat or cure hepatitis; for hepatitis C, oral antiviral pills cure more than 95% of people in 8 to 12 weeks. The research on cannabis and hepatitis is about side effects: whether it worsens liver scarring (most later studies say probably not, though one early study linked daily use to faster fibrosis) and whether it helped patients stick with the old interferon treatment.
Hepatitis means inflammation of the liver, most often caused by the hepatitis B or C virus. Because cannabis is processed by the liver, people with hepatitis reasonably ask whether it is safe, harmful or even helpful. Older articles, including the one that used to sit on this page, focused on a 2006 study from the interferon era. Treatment has changed completely since then. This guide explains what the research shows now. For other topics, see our cannabis research hub.
Evidence at a Glance: Cannabis and Hepatitis
| Claim | Evidence level | Source |
|---|---|---|
| Daily cannabis use does not speed liver fibrosis in hepatitis C | Limited evidence of no association | National Academies, 2017 |
| Cannabis use is not linked to more liver fibrosis in HCV or HIV/HCV | Moderate (meta-analysis of observational studies) | Farooqui et al., 2019 |
| Daily cannabis smoking speeds fibrosis in hepatitis C | Early finding, not confirmed by later cohorts | Hézode et al., 2005 |
| Cannabis users stayed on interferon treatment longer | Limited (one small observational study) | Sylvestre et al., 2006 |
| Cannabis use does not lower cure rates with modern antivirals | Limited (registry data) | Christensen et al., 2019 |
| CBD can raise liver enzymes | Strong (randomized trials, FDA label) | Florian et al., 2025 |
| Cannabis treats hepatitis B or C infection | No evidence | CDC |
Hepatitis C Treatment Today
Until about a decade ago, hepatitis C was treated with months of interferon injections and ribavirin, which caused fatigue, depression, nausea and weight loss, and cured only a portion of patients. That is the setting for most older cannabis studies. Today the CDC says oral direct-acting antivirals (DAAs) cure more than 95% of people in 8 to 12 weeks, with very few side effects. If you have hepatitis C, the single most important step is getting this treatment. Cannabis has no role in clearing the virus.
Does Cannabis Damage the Liver in Hepatitis C?
The 2005 French study that raised the alarm
A study of 270 untreated hepatitis C patients in Hepatology by Hézode and colleagues found that daily cannabis smokers were about three times as likely to have fast-progressing liver fibrosis, and more likely to have severe fibrosis, even after accounting for alcohol and other factors. The authors advised patients to avoid regular cannabis use. The same team’s earlier lab work had found that the body’s cannabinoid receptors help regulate liver scarring in animals.
Later studies found no clear link
- Canadian cohort, 2013. Following 690 people with HIV and hepatitis C over time, Brunet and colleagues found no evidence that smoking marijuana sped progression to significant fibrosis or cirrhosis. A small link with end-stage disease disappeared when they accounted for timing, which suggested sicker patients were using cannabis to manage symptoms rather than cannabis making them sicker.
- Meta-analysis, 2019. Pooling nine studies with nearly 6 million patients, Farooqui and colleagues found marijuana use did not increase the prevalence or progression of fibrosis in hepatitis C or HIV/hepatitis C.
- A second meta-analysis, 2018. Wijarnpreecha and colleagues pooled three hepatitis C cohorts and found a higher but not statistically significant risk of advanced fibrosis among cannabis users, with large differences between studies.
The National Academies concluded in 2017 that there is limited evidence of no association between daily cannabis use and the progression of liver fibrosis in hepatitis C. In plain terms: cannabis probably does not speed liver scarring, but the question is not fully closed, and people with advanced fibrosis or cirrhosis should be cautious.
Cannabis and Sticking With Treatment
The study often cited in older articles is a 2006 observational study by Sylvestre and colleagues in San Francisco. Among 71 people in recovery from substance use who were treated with interferon and ribavirin, the 22 who used cannabis were far less likely to quit treatment early (5% vs 33%) and more likely to be cured (54% vs 18%). The researchers did not give anyone cannabis; they compared people who already used it. With such a small group and no randomization, other differences between users and non-users could explain the results.
That question matters less now. Modern antivirals cause few side effects, so there is little to relieve. A large German registry study published in 2019 by Christensen and colleagues found that cannabis use did not significantly affect cure rates with direct-acting antivirals, which is reassuring for people who already use it.
Hepatitis B and Other Liver Diseases
There are no meaningful clinical studies of cannabis in hepatitis B. For fatty liver disease, now called metabolic dysfunction-associated steatotic liver disease (MASLD), observational studies, including the 2019 meta-analysis, have found lower rates among cannabis users. Associations like this can easily reflect other differences between users and non-users, and no trial has tested cannabis as a treatment.
Risks and Side Effects
- CBD and liver enzymes. In a 2025 FDA-led randomized trial in JAMA Internal Medicine, 5.6% of healthy adults taking CBD at 5 mg/kg a day for four weeks developed liver enzyme levels more than three times normal, compared with none on placebo. The FDA warns that CBD can cause liver injury. For anyone with hepatitis, that is a reason to avoid CBD products or use them only with monitoring.
- Drug processing. The liver breaks down cannabinoids. The prescribing label for Epidiolex, the FDA-approved CBD medicine, says exposure rises in moderate or severe liver impairment and calls for lower doses. Cannabinoids can also interact with other medicines processed by the liver.
- Alcohol. Combining cannabis with alcohol adds impairment, and alcohol is a proven driver of liver damage in hepatitis.
- Transplant evaluation. If you could ever need a liver transplant, ask your team about their cannabis policy early, since centers differ.
- General risks. Frequent use is linked to problem use, and smoking to respiratory symptoms. Our guide to cannabis safety covers the basics.
Talk to Your Doctor
Tell your hepatologist or primary care doctor about any cannabis or CBD use. Ask: Is my fibrosis stage a reason to avoid cannabis? Do I need liver tests if I use CBD? Will cannabis affect my treatment or transplant eligibility? If you have not been tested or treated for hepatitis C, ask about antiviral treatment first; it is short and usually curative. If you live in Washington and choose to use cannabis, licensed stores sell tested products; see our Washington dispensary directory and Washington marijuana laws.
Cannabis and Hepatitis FAQ
Is marijuana bad for your liver if you have hepatitis C?
Probably not in a major way, based on most studies since 2013, though one 2005 study linked daily smoking to faster scarring. The National Academies found limited evidence of no association. People with advanced liver disease should be cautious and talk to their doctor.
Can cannabis cure hepatitis C?
No. Oral direct-acting antiviral pills cure more than 95% of people in 8 to 12 weeks, according to the CDC. Cannabis has no effect on the virus.
Is CBD safe for people with hepatitis?
Use caution. CBD can raise liver enzymes, and in a 2025 FDA-led trial about 1 in 18 healthy adults on CBD had significant elevations within four weeks. Ask your doctor before using it and if you need liver tests.
Can I use cannabis during hepatitis C treatment?
A large registry study found cannabis use did not lower cure rates with modern antivirals. Tell your prescriber anyway so they can check for interactions.
Does cannabis help with hepatitis symptoms?
No trials have tested cannabis for hepatitis symptoms such as fatigue or nausea. An older study found users stayed on harsh interferon treatment longer, but that therapy is no longer standard.
For adults 21+ in legal states. General information, not medical advice. Talk to a doctor before using cannabis for a health condition.